本文選題：肺結(jié)核　切入點(diǎn)：黃芪注射液　出處：《山東醫(yī)藥》2017年24期

【摘要】：目的系統(tǒng)評(píng)價(jià)黃芪注射液對(duì)常規(guī)抗肺結(jié)核化療藥物的減毒增效作用,為黃芪注射液的臨床應(yīng)用提供科學(xué)依據(jù)。方法計(jì)算機(jī)檢索CBM、CNKI、維普、萬方、Pub Med、Embase、ISI、Cochrane Library、中國及美國臨床試驗(yàn)注冊(cè)中心等數(shù)據(jù)庫。應(yīng)用Cochrane協(xié)作網(wǎng)隨機(jī)對(duì)照研究質(zhì)量評(píng)價(jià)標(biāo)準(zhǔn)評(píng)價(jià)納入研究質(zhì)量,并對(duì)相關(guān)數(shù)據(jù)進(jìn)行Meta分析。結(jié)果納入22項(xiàng)隨機(jī)對(duì)照研究,肺結(jié)核患者2 320例,黃芪注射液聯(lián)合化療組(黃芪+化療組)1 149例、單純化療組1 171例。Meta分析結(jié)果顯示,治療2~4個(gè)月時(shí),黃芪+化療組痰菌轉(zhuǎn)陰率、病灶吸收改善率、結(jié)核空洞縮小率、癥狀體征改善率均高于單純化療組,消化道反應(yīng)、肝功能損傷、皮疹及視神經(jīng)炎發(fā)生率均低于單純化療組(P均0.05);黃芪+化療組治療1~2年細(xì)菌學(xué)復(fù)發(fā)率低于單純化療組(P0.05)。結(jié)論黃芪注射液輔助治療肺結(jié)核可提高常規(guī)抗結(jié)核化療藥物的治療效果,并可減輕化療藥物的不良反應(yīng)。
[Abstract]:Objective to evaluate the attenuated and synergistic effect of Huangqi injection on conventional anti-tuberculosis chemotherapy drugs, and to provide scientific basis for clinical application of Astragalus membranaceus injection. Pub Medsite Embase, Iris Cochrane Library, Chinese and American Clinical trial Registry and other databases. The quality evaluation criteria of randomized controlled study with Cochrane collaboration network were used to evaluate the quality of the study, and the relevant data were analyzed by Meta. The results were included in 22 randomized controlled trials. There were 2 320 cases of pulmonary tuberculosis, 1 149 cases of astragalus injection combined chemotherapy group and 1 171 cases of simple chemotherapy group. The results of Meta analysis showed that after 2 ~ 4 months of treatment, the rate of sputum bacteria turning negative and the rate of improvement of focus absorption in astragalus chemotherapy group were improved. The reduction rate of tuberculosis cavity, the improvement rate of symptoms and signs were higher than those of chemotherapy group, digestive tract reaction, liver function injury, The incidence of skin rash and optic neuritis was lower than that of chemotherapy group (P < 0.05), the bacteriological recurrence rate of astragalus chemotherapy group was lower than that of chemotherapy group for 1 ~ 2 years (P 0.05). Conclusion Astragalus injection adjuvant treatment of pulmonary tuberculosis can improve the therapeutic effect of routine anti-tuberculosis chemotherapy drugs. And can alleviate the adverse reaction of chemotherapeutic drugs.
【作者單位】： 遵義醫(yī)學(xué)院附屬醫(yī)院;
【基金】：國家自然科學(xué)基金資助項(xiàng)目(81360002)
【分類號(hào)】：R521

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 劉碧堅(jiān),夏冬文,鄭景輝,楊芳;黃芪注射液治療急性黃疸型肝炎的臨床評(píng)價(jià)[J];遼寧藥物與臨床;2000年01期

2 徐建芳;;黃芪注射液佐治老年活動(dòng)期肺結(jié)核50例[J];中國中醫(yī)藥科技;2010年03期

3 何炳福;黃芪注射液對(duì)44例慢性乙型肝炎患者γ球蛋白的影響[J];中西醫(yī)結(jié)合肝病雜志;1993年01期

4 江連枝;;黃芪注射液與伐昔洛韋治療高復(fù)發(fā)性生殖器皰疹的對(duì)比研究[J];中國藥物經(jīng)濟(jì)學(xué);2013年06期

5 陳業(yè)芝;黃芪注射液佐治肺結(jié)核30例臨床觀察[J];廣西醫(yī)學(xué);2003年07期

6 于杰,黃自存;黃芪注射液治療急性黃疸型肝炎82例[J];中西醫(yī)結(jié)合肝病雜志;1999年02期

7 陳艷麗;張婷婷;;黃芪注射液聯(lián)合抗結(jié)核藥治療肺結(jié)核療效觀察[J];世界中西醫(yī)結(jié)合雜志;2013年10期

8 神兆玉,彭華彬,神克蘭;丹參與黃芪注射液聯(lián)用治療慢性肝炎臨床觀察[J];濱州醫(yī)學(xué)院學(xué)報(bào);2000年06期

9 楊永瑞,楊進(jìn)玉;強(qiáng)力寧合黃芪注射液治療急性乙型病毒性肝炎62例[J];現(xiàn)代中西醫(yī)結(jié)合雜志;1999年08期

10 來中海,江振英,李秋玉;黃芪注射液佐治老年活動(dòng)期肺結(jié)核近期療效觀察[J];中國中西醫(yī)結(jié)合雜志;2004年07期

，

本文編號(hào)：1670320